Columbia is part of a new consortium to identify rare genetic variants that may protect against, or contribute to Alzheimer’s disease.
Recent research at Columbia has shed light on an important risk marker for Alzheimer’s—”white matter hyperintensities” (WMH).
Researchers from CUMC, Weill Cornell, and Brandeis have devised a new approach to the treatment of Alzheimer’s involving the retromer protein complex.
Dr. Richard Mayeux dispels common misconceptions, and explains the basics, about Alzheimer’s disease.
Neurologist Scott A. Small participated in a Kavli Foundation roundtable on the link between the brain’s ability to make new cells and age-related memory loss.
CUMC researchers have clarified three fundamental issues about Alzheimer’s: where it starts, why it starts there, and how it spreads.